Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part study First-in-class therapeutic targets Alveolar Epithelial Type 2 (AEC2) cells with the aim to halt disease progression and promote repair of fibrotic damage in IPF The ORBIT-IPF is…
Genmab A/S (GMAB) reported positive results form a Phase 3 trial evaluating Petosemtamab plus Keytruda (pembrolizumab) as a first-line treatment for patients with PD-L1 positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival and tumor…
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose. There were 545 patients included in the analysis from the registry and 1027 patients from Duke’s EHRs. Both cohorts were predominantly…
Genmab (GMAB) announced topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an investigational IgG1-bispecific anti... Genmab announces results from Phase 3 LiGeR-HN1 trial of petosemtamab Genmab (GMAB) announced topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an…
Genmab (GMAB) stock surges as head and neck cancer cuts death risk by 50%, with Merck’s (MRK) Keytruda sending Bicara Therapeutics (BCAX) lower. Read more here. Genmab (GMAB) ADRs climbed nearly 15% on Wednesday after the Danish drugmaker said that its bispecific…
On the final day of the Alzheimer’s Association International Conference, attention at the plenary session turned to another common dementia. Frontotemporal dementia (FTD) was the topic of a... On the final day of the Alzheimer’s Association International Conference, attention at the…
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Forlong Biotechnology Announces First Patient…
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient improvements observed as early as Week 4 and sustained through 52 weeks Late-breaking…
Analyses of achievement of minimal symptom expression in generalized myasthenia gravis (gMG) patients receiving either ZILBRYSQ® (zilucoplan) or RYSTIGGO® (rozanolixizumab-noli) treatment: 120-week post hoc analysis of Phase 3 RAISE-XT open-label extension for zilucoplan and Phase 3 MycarinG study for rozanolixizumab and its…
Oct 08, 2026, 08:00 ET – Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – EDG-15400 is an investigational, oral, selective cardiac sarcomere modulator that…
Results of clinical trials of new biotech medicines: phase 1 to 3 readouts, trial successes and failures, and trial design.
An article joins this feed when it matches these terms. Each one is also a search of its own.